涎腺导管癌：一种侵袭性的涎腺癌，具有靶向治疗的机会。
Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy.
机构信息
Integrative Therapeutics Program, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD, United States; Department of Otolaryngology - Head and Neck Surgery, Johns Hopkins University, Bethesda, MD, United States.
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD, United States.
出版信息
Oral Oncol. 2017 Nov;74:40-48. doi: 10.1016/j.oraloncology.2017.09.008. Epub 2017 Sep 21.
Abstract
Salivary duct carcinoma (SDC) is a rare, aggressive salivary malignancy that is often diagnosed at an advanced stage. Previously, little was known about outcomes of this disease due to its rarity. In the past several years, much has been learned about salivary duct carcinoma after publication of outcomes from several large single-institution series and national database searches. Recent studies of genomic alterations have helped elucidate the biology and pathogenesis of this aggressive disease. Here we review outcomes of the disease, effects of treatment, prognostic factors, and genomic alterations in SDC. Studies of targeted therapy and promising future directions are also discussed.
摘要
唾液腺癌（SDC）是一种罕见的侵袭性唾液恶性肿瘤，通常在晚期诊断。由于其罕见性，以前对这种疾病的结果知之甚少。在过去的几年中，在发表了几个大型单机构系列和国家数据库搜索的结果后，人们对唾液腺癌有了更多的了解。最近对基因组改变的研究有助于阐明这种侵袭性疾病的生物学和发病机制。在这里，我们回顾了疾病的结果、治疗效果、预后因素和 SDC 的基因组改变。还讨论了靶向治疗的研究和有前途的未来方向。
相似文献
1
Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy.
Oral Oncol. 2017 Nov;74:40-48. doi: 10.1016/j.oraloncology.2017.09.008. Epub 2017 Sep 21.
2
A 20-Year Review of 75 Cases of Salivary Duct Carcinoma.
JAMA Otolaryngol Head Neck Surg. 2016 May 1;142(5):489-95. doi: 10.1001/jamaoto.2015.3930.
3
Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications.
Hum Pathol. 2019 Nov;93:37-47. doi: 10.1016/j.humpath.2019.08.009. Epub 2019 Aug 19.
4
Salivary duct carcinoma of the supraglottis with a distinct presentation: A case report and literature review.
Medicine (Baltimore). 2018 Mar;97(11):e0095. doi: 10.1097/MD.0000000000010095.
5
First-Line Treatment of Widely Metastatic -Mutated Salivary Duct Carcinoma With Combined BRAF and MEK Inhibition.
J Natl Compr Canc Netw. 2018 Oct;16(10):1166-1170. doi: 10.6004/jnccn.2018.7056.
6
Prognostic factors and oncologic outcomes of 56 salivary duct carcinoma patients in a single institution: high rate of systemic failure warrants targeted therapy.
Oral Oncol. 2014 Nov;50(11):e64-6. doi: 10.1016/j.oraloncology.2014.08.010. Epub 2014 Sep 11.
7
Genomic alteration in rare subtype of sarcomatoid salivary duct carcinoma.
Pathol Res Pract. 2021 Dec;228:153678. doi: 10.1016/j.prp.2021.153678. Epub 2021 Oct 29.
8
A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands.
Int J Cancer. 2018 Aug 15;143(4):758-766. doi: 10.1002/ijc.31353. Epub 2018 Mar 23.
9
Three new cases of salivary duct carcinoma in the palate: a radiologic investigation and review of the literature.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 Jun;95(6):752-60. doi: 10.1067/moe.2003.246.
10
Early T Stage Salivary Duct Carcinoma: Outcomes and Implications for Patient Counseling.
Otolaryngol Head Neck Surg. 2015 Nov;153(5):795-8. doi: 10.1177/0194599815601659. Epub 2015 Aug 25.
引用本文的文献
1
The effect of androgen blockade on [Ga]Ga-PSMA-11 and [F]FDG PET uptake in patients with recurrent or metastatic salivary duct carcinoma: a prospective imaging study.
EJNMMI Res. 2025 Jul 15;15(1):86. doi: 10.1186/s13550-025-01275-x.
2
Clinical diagnosis, treatment, and survival analysis of 61 cases of salivary duct carcinoma: a retrospective study.
PeerJ. 2025 Jul 4;13:e19626. doi: 10.7717/peerj.19626. eCollection 2025.
3
Prognostic factors and survival outcomes in patients with salivary duct carcinoma: a retrospective cohort study.
BMC Oral Health. 2025 Jan 16;25(1):73. doi: 10.1186/s12903-025-05427-2.
4
Neratinib and the Role of Anti-HER2 Therapy in Salivary Duct Carcinoma.
Cancer Rep (Hoboken). 2025 Jan;8(1):e70065. doi: 10.1002/cnr2.70065.
5
Salivary Gland Oncocytomas. A Systematic Review.
Head Neck Pathol. 2024 Nov 30;18(1):126. doi: 10.1007/s12105-024-01730-6.
6
Molecular landscape of salivary gland malignancies. What is already known?
Contemp Oncol (Pozn). 2024;28(3):201-216. doi: 10.5114/wo.2024.144288. Epub 2024 Oct 15.
7
Salivary duct carcinoma in the submandibular gland: A rare case report with differential diagnosis.
J Oral Maxillofac Pathol. 2024 Apr-Jun;28(2):311-314. doi: 10.4103/jomfp.jomfp_476_23. Epub 2024 Jul 11.
8
Recurrence after primary salivary gland carcinoma: Frequency, survival, and risk factors.
Head Neck. 2025 Jan;47(1):47-56. doi: 10.1002/hed.27880. Epub 2024 Jul 27.
9
Fingertip cutaneous metastasis of salivary duct carcinoma secondary to scald: A unique case report and a brief review of literature (following CARE guidelines).
Medicine (Baltimore). 2024 Jul 19;103(29):e38965. doi: 10.1097/MD.0000000000038965.
10
A 22-year single institution review of 119 cases of salivary duct carcinoma.
Laryngoscope Investig Otolaryngol. 2024 Mar 23;9(2):e1234. doi: 10.1002/lio2.1234. eCollection 2024 Apr.
本文引用的文献
1
Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study.
Am J Clin Oncol. 2018 Nov;41(11):1083-1088. doi: 10.1097/COC.0000000000000429.
2
Characterization, treatment and outcomes of salivary ductal carcinoma using the National Cancer Database.
Oral Oncol. 2017 Aug;71:41-46. doi: 10.1016/j.oraloncology.2017.05.005. Epub 2017 Jun 5.
3
New concepts of personalized therapy in salivary gland carcinomas.
Oral Oncol. 2017 May;68:103-113. doi: 10.1016/j.oraloncology.2017.02.018. Epub 2017 Mar 18.
4
Salivary Duct Carcinoma: An Update on Morphologic Mimics and Diagnostic Use of Androgen Receptor Immunohistochemistry.
Head Neck Pathol. 2017 Sep;11(3):288-294. doi: 10.1007/s12105-017-0798-x. Epub 2017 Mar 20.
5
Androgen Receptor Signaling in Salivary Gland Cancer.
Cancers (Basel). 2017 Feb 8;9(2):17. doi: 10.3390/cancers9020017.
6
Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature.
Head Neck. 2017 Mar;39(3):E40-E44. doi: 10.1002/hed.24634. Epub 2016 Dec 22.
7
Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma: a multi-institutional study in Japan.
Oncotarget. 2017 Jan 3;8(1):1083-1091. doi: 10.18632/oncotarget.13565.
8
Blockade of Androgen-induced Malignant Phenotypes by Flutamide Administration in Human Salivary Duct Carcinoma Cells.
Anticancer Res. 2016 Nov;36(11):6071-6075. doi: 10.21873/anticanres.11196.
9
Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment.
Ann Oncol. 2017 Jan 1;28(1):110-115. doi: 10.1093/annonc/mdw442.
10
MDM2 and CDK4 amplifications are rare events in salivary duct carcinomas.
Oncotarget. 2016 Nov 15;7(46):75261-75272. doi: 10.18632/oncotarget.12127.
Zotero 插件